Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The benzodiazepine antagonist, Ro 15-1788 does not decrease ethanol withdrawal convulsions in rats.

H J Little, S C Taylor, D J Nutt

    European Journal of Pharmacology
    |January 8, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Human brain changes after first psilocybin use.

    Nature communications·2026
    Same author

    Serotonergic psychedelics for depression: A comprehensive overview.

    International review of neurobiology·2025
    Same author

    Suicidal Ideation in Medicinal Cannabis Patients: A 12-Month Prospective Study.

    Archives of suicide research : official journal of the International Academy for Suicide Research·2024
    Same author

    Psilocybin and Other Classic Psychedelics in Depression.

    Current topics in behavioral neurosciences·2023
    Same author

    Canalization and plasticity in psychopathology.

    Neuropharmacology·2022
    Same author

    Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21.

    Psychopharmacology·2021
    Same journal

    Astaxanthin inhibits platelet-mediated thrombosis via suppression of bidirectional αIIbβ3 signaling.

    European journal of pharmacology·2026
    Same journal

    Repurposing of alogliptin to mitigate experimentally-induced ulcerative colitis and its associated pulmonary injury in rats through regulating inflammatory, necroptotic, and ER stress pathways.

    European journal of pharmacology·2026
    Same journal

    Erianin ameliorates liver fibrosis through the PRDX3/NLRX1 axis.

    European journal of pharmacology·2026
    Same journal

    4-Octyl itaconate attenuates renal calculi formation by inhibiting ferroptosis and oxidative stress via the Nrf2-HO-1/SLC7A11 axis.

    European journal of pharmacology·2026
    Same journal

    VER155008 rescues cognitive impairment in P301S tauopathy mice by promoting HSPA8-mediated lipophagy.

    European journal of pharmacology·2026
    Same journal

    Okanin alleviates osteoarthritis by suppressing oxidative stress and pyroptosis via Nrf2/HO-1 activation.

    European journal of pharmacology·2026
    See all related articles

    Ro 15-1788 did not alleviate ethanol withdrawal convulsions in rats. This suggests that the convulsions are not caused by endogenous benzodiazepine inverse agonists, as the antagonist Ro 15-1788 was ineffective.

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Addiction Research

    Background:

    • Recent studies suggest benzodiazepine binding activity in alcoholic urine during withdrawal.
    • Ethanol withdrawal syndrome is a complex condition with various physiological manifestations.
    • Benzodiazepines are commonly used to manage alcohol withdrawal symptoms.

    Purpose of the Study:

    • To investigate the efficacy of the benzodiazepine antagonist Ro 15-1788 in mitigating ethanol withdrawal-induced convulsions in a rat model.
    • To explore the potential role of endogenous benzodiazepine inverse agonists in ethanol withdrawal convulsions.

    Main Methods:

    • Adult male rats were administered ethanol to induce dependence.
    • Ethanol withdrawal was precipitated, and convulsion severity was assessed.

    Related Experiment Videos

  • Rats were treated with the benzodiazepine antagonist Ro 15-1788.
  • Convulsion frequency and intensity were compared between treated and control groups.

    • Main Results:

    • Ro 15-1788 administration did not significantly reduce the incidence or severity of ethanol withdrawal convulsions.
    • The antagonist's ineffectiveness suggests it did not block the action of any endogenous compounds mediating convulsions.

    Conclusions:

    • The findings indicate that ethanol withdrawal convulsions in rats are unlikely to be mediated by endogenous benzodiazepine inverse agonists.
    • Ro 15-1788 is not an effective treatment for ethanol withdrawal-induced seizures.
    • Further research is needed to elucidate the precise neurobiological mechanisms underlying alcohol withdrawal convulsions.